On Monday, Hartford Financial Services Group Inc (NYSE:HIG)’s shares declined -1.30% to $41.00.
Hartford Financial Services Group Inc (HIG) is now the exclusive business and homeowners insurance of Major League Baseball, also becoming the presenting sponsor of the sport’s Reliever of the Year Awards.
All-time saves leader Mariano Rivera, for whom the American League Reliever of the Year Award is named, will serve as national ambassador for Hartford, appearing in advertising and attending events on behalf of the company, it said in a joint news release with MLB.
Based in the Connecticut city of the same name, Hartford also will become the exclusive benefits partner of MLB, and it will sponsor five individual teams this season and more in 2016.
The Reliever of the Year Award, named after Rivera in the AL and Trevor Hoffman in the National League, were first issued last season. Former Atlanta Braves pitcher Craig Kimbrel won in the NL after a 47-save season in which his earned run average was 1.61. The Kansas City Royals’ Greg Holland took the AL award, saving 46 games with a 1.44 ERA.
The Hartford Financial Services Group, Inc., through its auxiliaries, provides insurance and financial services to individual and business customers primarily in the United States. The company’s Commercial Lines segment offers workers compensation, property, automobile, marine, umbrella, liability, and livestock coverage’s, in addition to customized insurance products and risk administration services, counting professional liability, bond, and specialty casualty coverage’s.
Abercrombie & Fitch Co. (NYSE:ANF)’s shares dropped -0.71% to $22.29.
Abercrombie & Fitch Co. (ANF) declared that Jonathan Ramsden, Chief Operating Officer will present at the Jefferies 2015 Global Consumer Conference on Tuesday, June 23, 2015 at 10:00 AM, Eastern Time.
The audio portion of the presentation and the accompanying slides will be accessible to the general public on the “Investors” section of the Company`s website at www.abercrombie.com at about 10:00 AM, Eastern Time on Tuesday, June 23, 2015.
Abercrombie & Fitch Co., through its auxiliaries, operates as a specialty retailer of apparel for men, women, and kids. The company operates through three segments: U.S. Stores, International Stores, and Direct-to-Consumer. It sells various products, such as casual sportswear apparel comprising knit and woven shirts, graphic T-shirts, fleece, jeans and woven pants, shorts, sweaters, and outerwear; personal care products; and accessories for men, women, and kids under the Abercrombie & Fitch, abercrombie kids, and Hollister brand names.
At the end of Monday’s trade, Ventas, Inc. (NYSE:VTR)‘s shares surged 0.61% to $63.95.
Ventas, Inc. (VTR) declared that administration will make a presentation regarding the Company at the NAREIT REITWeek 2015 Conference in New York, New York on Wednesday, June 10, 2015, at 4:15 p.m. Eastern Time.
Ventas, Inc. is a publicly owned real estate investment trust. The firm engages in investment, administration, financing, and leasing of properties in the healthcare industry. It invests in the real estate markets of the United States and Canada. The firm primarily invests in healthcare-related facilities counting hospitals, skilled nursing facilities, senior housing facilities, medical office buildings, and other healthcare related facilities.
Northwest Biotherapeutics, Inc (NASDAQ:NWBO), ended its Monday’s trading session with 5.83% gain, and closed at $9.98.
Northwest Biotherapeutics, Inc (NWBO) a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, over the weekend in Chicago released promising new data on their Phase I trial of DCVax-Direct for direct injection into all types of inoperable solid tumors.
The patients enrolled in the trial had late stage cancers, with an average of three inoperable tumors. The patients had failed multiple prior therapies and had a poor prognosis.
The trial enrolled 40 patients, and 39 were evaluable. A conservative treatment regimen was used. Although the patients had multiple inoperable tumors, only 1 tumor was injected with DCVax-Direct. The treatments comprised of only 3 injections in the first 2 weeks (Day 0, 7 and 14), and up to 3 additional injections spaced months apart thereafter (Weeks 8, 16 and 32), over a total period of 8 months.
Patients typically received their first injection about 1-1/2 months after recruitment. Four patients are still in the process of concluding the study visits, and data collection is ongoing on all of the patients.
The trial tested three different dose levels of DCVax-Direct, two different methods of activating the dendritic cells that comprise DCVax-Direct, and a dozen different cancers. Findings to date comprise encouraging survival data and substantial induction of immune checkpoint expression (PDL-1).
Northwest Biotherapeutics, Inc., a biotechnology company, discovers and develops immunotherapy products to treat cancer in the United States and internationally. It is involved in the development of DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
